Dubika Tablet 5/40mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Sama Pharmaceutical Co., Ltd.
MFDS item code 201500291 · Approved 2015.01.20
This product's status changed to Expired on 2025.01.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medicine is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It effectively lowers blood pressure and helps in managing blood pressure by reducing the risk of cardiovascular complications.
Administer 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted before administering this medicine; however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive agents and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, 2. Do not administer to the following patients.) ∘Older adults: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In older adults, blood pressure should be monitored closely and more frequently.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm or death to the fetus and neonate if taken during pregnancy in the second and third trimesters. It should be stopped immediately if pregnancy is confirmed. Patients with allergies to this drug's active ingredients or similar substances, pregnant or breastfeeding women, those with severe liver impairment, patients with heart or biliary issues, kidney dialysis patients, those in severe shock, and certain diabetic patients and those with severely decreased kidney function should not be administered this drug. This drug should be used with caution in patients with dehydration or low sodium levels, very low blood pressure, severe heart disease, impaired kidney function, and those with decreased liver function, and blood pressure and conditions should be closely monitored at the initiation of treatment. This drug may cause side effects such as dizziness, headache, low blood pressure, edema, digestive disorders, skin rash, etc., so if any abnormal symptoms occur, consult with a healthcare professional immediately. Use of this drug during pregnancy should be avoided, especially after the second trimester, as it can pose serious risks to the fetus. Breastfeeding women should be cautious as this drug may be transmitted through breast milk and should consult a doctor about stopping breastfeeding while taking the medication. The safety and effectiveness in pediatric patients under 18 years old have not been established and its use is not recommended. In the elderly, kidney and liver functions may be reduced, so treatment should begin at a lower dose and be administered cautiously. In the event of overdose, symptoms such as hypotension and tachycardia may occur, and immediate medical treatment should be sought. This drug should be stored in a place protected from moisture, heat, and direct sunlight, out of reach of children. Interactions may occur with other drugs; if the patient is taking other medications, it is essential to inform the healthcare provider, and it is advisable to avoid taking this drug with grapefruit juice.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C. Therefore, store it safely in a cool and dry place until use.
Pale yellow circular film-coated tablet
28 tablets/box [14 tablets/PTP x 2], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Sama Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.